Ensign Peak Advisors Inc Acquires 7,248 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Ensign Peak Advisors Inc lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.2% during the 4th quarter, Holdings Channel reports. The firm owned 41,395 shares of the medical equipment provider’s stock after buying an additional 7,248 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Lantheus were worth $3,703,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in LNTH. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Lantheus in the 4th quarter worth about $36,183,000. Swedbank AB grew its holdings in shares of Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Finally, Keybank National Association OH bought a new stake in shares of Lantheus in the 4th quarter worth about $27,526,000. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LNTH. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Finally, B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $132.67.

Lantheus Stock Down 0.2%

Shares of NASDAQ LNTH opened at $78.81 on Thursday. The firm’s 50-day simple moving average is $98.18 and its 200 day simple moving average is $93.72. The company has a market cap of $5.40 billion, a price-to-earnings ratio of 13.11 and a beta of 0.23. Lantheus Holdings, Inc. has a 12-month low of $75.00 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the previous year, the company posted $1.69 earnings per share. The business’s revenue for the quarter was up .8% on a year-over-year basis. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.